Top Line: What is the role of radiation in managing neovascular, age-related macular degeneration (nAMD)?
The Study: nAMD is a major cause of blindness, and treatment requires frequent intravitreal injections of anti-VEGF drugs. Those drugs cost a fortune with >$10 billion spent in the US each year just for treating nAMD. A randomized, phase 2 trial (INTREPID) found that single-fraction stereotactic radiation (SRT) significantly reduced the number of anti-VEGF injections for patients with nAMD. In this masked, sham-controlled trial, 411 patients with chronic nAMD requiring anti-VEGF injections were randomized to receive 16 Gy in 1 fraction or sham SRT to the macula. SRT was delivered using a specialized system with a stabilization device for the eye and a robotic treatment delivery platform. They then received anti-VEGF injections based on standard retreatment criteria. At the 8 year mark, SRT resulted in a 22% reduction in ranibizumab injections from a cumulative mean of 13.3 to 10.7 injections. There was no significant detriment in visual acuity with SRT and no increase in toxicity. Was it worth it? Given the significant cost of anti-VEGF therapy, the reduction in injections with SRT more than paid for its cost with an estimated savings of >£500.
TBL: Single fraction radiation to the macula significantly reduces the burden of intravitreal anti-VEGF injections for patients with nAMD. | Jackson, Lancet 2024
The Study: nAMD is a major cause of blindness, and treatment requires frequent intravitreal injections of anti-VEGF drugs. Those drugs cost a fortune with >$10 billion spent in the US each year just for treating nAMD. A randomized, phase 2 trial (INTREPID) found that single-fraction stereotactic radiation (SRT) significantly reduced the number of anti-VEGF injections for patients with nAMD. In this masked, sham-controlled trial, 411 patients with chronic nAMD requiring anti-VEGF injections were randomized to receive 16 Gy in 1 fraction or sham SRT to the macula. SRT was delivered using a specialized system with a stabilization device for the eye and a robotic treatment delivery platform. They then received anti-VEGF injections based on standard retreatment criteria. At the 8 year mark, SRT resulted in a 22% reduction in ranibizumab injections from a cumulative mean of 13.3 to 10.7 injections. There was no significant detriment in visual acuity with SRT and no increase in toxicity. Was it worth it? Given the significant cost of anti-VEGF therapy, the reduction in injections with SRT more than paid for its cost with an estimated savings of >£500.
TBL: Single fraction radiation to the macula significantly reduces the burden of intravitreal anti-VEGF injections for patients with nAMD. | Jackson, Lancet 2024

